Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma
Authors:
Open Access
- 9 February 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 157 (4) , 335-342
Abstract
Historically, the outcome of patients with stage III melanoma was poor with a high risk of relapse.1,2 Adjuvant therapy with monoclonal antibodies targeting cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) and adjuvant therapies targeting BRAF and MEK have improved the relapse-free survival (RFS). Still, 40% to 50% of patients with high-risk stage III melanoma relapse within 3 to 5 years.3-5 Results of early clinical trials show that neoadjuvant therapy with checkpoint inhibitors induces high pathologic response rates, especially with the combination of anti-PD-1 and anti-CTLA-4 antibodies, with subsequent durable RFS outcomes that may outperform adjuvant therapy.6-8Keywords
This publication has 29 references indexed in Scilit:
- MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysisThe Breast, 2018
- Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI ProcedureAnnals of Surgical Oncology, 2018
- Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary DissectionJournal of Clinical Oncology, 2016
- Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0–T4, N1–N2) Who Receive Neoadjuvant ChemotherapyAnnals of Surgery, 2016
- Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer PatientsAnnals of Surgery, 2015
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- Morbidity and prognosis after therapeutic lymph node dissections for malignant melanomaEuropean Journal of Surgical Oncology, 2007
- Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanomaEuropean Journal of Surgical Oncology, 2006
- Morbidity after axillary sentinel lymph node biopsy in patients with cutaneous melanomaEuropean Journal of Surgical Oncology, 2005